Salus Science Corporation

Keisuke Taniuchi, President and Representative Director of our company, was the lead author of a paper published in Human Cell on a “novel chemotherapeutic regimen for pancreatic cancer” that we are working to commercialize in the clinic.

In practice, gemcitabine plus nab-paclitaxel (GnP) is the first-line chemotherapy for patients with advanced pancreatic cancer. In this paper, we investigated the efficacy of GnP combined with rapamycin, an mTOR inhibitor. We conducted a drug efficacy evaluation study using “human pancreatic cancer organoid transplanted mice,” which are currently marketed by our company, and found that pancreatic cancer tumors were significantly smaller in mice treated with rapamycin in combination with GnP compared to mice treated with GnP. The study showed that chemotherapy combining GnP with rapamycin may be a new treatment option for patients with advanced pancreatic cancer who have few treatment options.

Source: https://pubmed.ncbi.nlm.nih.gov/39794664/

NEWS

Keisuke Taniuchi, President and Representative Director of our company, was the lead author of a paper published in Human Cell on a “novel chemotherapeutic regimen for pancreatic cancer” that we are working to commercialize in the clinic.